Skip to content
naulon
Not checkedNot checked for notices yet.

Therapeutic Effects of Atranorin towards the Proliferation of Babesia and Theileria Parasites

Amany Magdy Beshbishy, Gaber El-Saber Batiha, Luay Alkazmi and 5 more

Pathogens · 2020

doi:10.3390/pathogens9020127 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Atranorin (ATR), is a compound with multidirectional biological activity under different in vitro and in vivo conditions and it is effective as an antibacterial, antiviral, antiprotozoal and anti-inflammatory agent. In the current study, the in vitro as well as in vivo chemotherapeutic effect of ATR as well as its combined efficacy with the existing antibabesial drugs (diminazene aceturate (DA), atovaquone (AV) and clofazimine (CF)) were investigated on six species of piroplasm parasites. ATR suppressed <i>B. bovis, B. bigemina, B. divergens, B. caballi</i> and <i>T. equi</i> multiplication in vitro with IC<sub>50</sub> values of 98.4 &#177; 4.2, 64.5 &#177; 3.9, 45.2 &#177; 5.9, 46.6 &#177; 2.5, and 71.3 &#177; 2.7 &#181;M, respectively. The CCK test was used to examine ATR&#8217;s cytotoxicity and adverse effects on different animal and human cell lines, the main hosts of piroplasm parasites and it showed that ATR affected human foreskin fibroblasts (HFF), mouse embryonic fibroblast (NIH/3T3) and Madin-Darby Bovine Kidney (MDBK) cell viability in a dose-related effect with a moderate selective index. The combined efficacy of ATR with DA, CF, and AV exhibited a synergistic and additive efficacy toward all tested species. In the in vivo experiment, ATR prohibited <i>B. microti</i> multiplication in mice by 68.17%. The ATR-DA and ATR-AV combination chemotherapies were more potent than ATR monotherapy. These results indicate the prospects of ATR as a drug candidate for piroplasmosis treatment.

Abstract licence: CC BY

Cited by papers we hold3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.